Developer docs
API playgroundTry for free, no card

Search company profiles

Voronoi

Full company profile

uuid00021sx

Namestring
Voronoi
Legal namestring
Voronoi, Inc.
Websiteurl
voronoi.io
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Voronoi is a precision medicine biotechnology company founded in 2015 and headquartered in Songdo, Incheon, South Korea, that develops novel kinase inhibitors and target protein degraders for oncology and autoimmune diseases. The company's core technology is VORONOMICS, a proprietary AI-augmented drug design platform that integrates in-house wet-lab kinase profiling data (~550,000 assay data points per year) with machine learning feedback loops and an in vivo animal testing center to identify and optimize candidates with high selectivity and blood-brain barrier penetration, compressing candidate identification timelines to 1–1.5 years versus an industry-standard ~3 years. Voronoi maintains an 11-program pipeline spanning EGFR-mutant NSCLC (VRN11), HER2-positive solid tumors (VRN10), EGFR/HER2 exon 20 insertions (VRN07, partnered with ORIC), synthetic-lethality targets (VRN16/PKMYT1, VRN19/USP1), an autoimmune therapy (VRN04/RIPK1, transferred to Anvia), and an inhaled PAH therapy (VRN13). As of its 2022 securities filing, the company held 174 patents (186 total IP assets), ranking first in Korea and ninth globally in small molecule drug patents.

Short descriptiontext

Voronoi is a Korean clinical-stage biotech using its AI-augmented VORONOMICS platform to develop precision kinase inhibitors for oncology and autoimmune diseases, commercializing through global out-licensing deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIncheon, South Korea
HQ citystring
Incheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kinase inhibitor discovery, precision oncology therapeutics, targeted cancer therapy, pharmaceutical out-licensing, AI drug discovery platform
Industry4 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
Product category
Precision Oncology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing / License-Out Deals
TypeLicensing Royalties
Description

Voronoi's primary revenue model is out-licensing its proprietary drug candidates to global pharmaceutical and biotech companies. The company discovers and develops pipeline candidates through Phase 1 clinical stage, then executes license-out agreements that generate upfront payments, milestone payments, and ongoing royalties. Reference deals include: ORIC Pharmaceuticals (EGFR/HER2 exon20, ~$621M total), Bridgepoint (DYRK1A autoimmune, ~$323.5M total), Pyramid Biosciences (MPS1, ~$846M total), and Anvia Therapeutics (VRN04 RIPK1, equity + milestone payments). Cumulative technology export value exceeds KRW 3 trillion.

voronoi.io
2Government Research Grants
TypeProfessional Services
Description

Voronoi receives non-dilutive funding from Korea's National New Drug Development Project (KDDF) for preclinical and candidate discovery stages. Multiple pipeline programs (VRN04, VRN08, VRN10, VRN11, VRN13) have been selected for government support.

voronoi.io
3Equity Capital / Public Market
TypeOne Time License
Description

Voronoi is listed on KOSDAQ (ticker: 310210). The company raises dilutive capital through public offerings, rights offerings, and convertible bond issuances to fund clinical development. IPO was completed in June 2022. Subsequent capital raises include a KRW 450 billion rights offering in 2023.

voronoi.io
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Voronoi discovers and develops targeted kinase inhibitors and related small molecule therapeutics for oncology (EGFR-mutant NSCLC, HER2-positive solid tumors, CCNE1-amplified cancers, BRCA1/2-mutant cancers) and autoimmune/Pulmonary arterial hypertension indications using its proprietary VORONOMICS AI-augmented drug design platform. Its portfolio includes VRN11 (4th-generation EGFR inhibitor), VRN10 (HER2-selective inhibitor), VRN07 (EGFR/HER2 exon20 inhibitor partnered with ORIC), VRN16 (PKMYT1 inhibitor), VRN19 (USP1 inhibitor), VRN13 (inhaled PDGFR inhibitor for PAH), and VRN04 (RIPK1 inhibitor transferred to Anvia Therapeutics). Revenue is generated primarily through out-licensing these pipeline assets to global pharmaceutical partners in exchange for upfront, milestone, and royalty payments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • VRN11 Phase 1a: DCR 96.8% (30/31) in heavily pretreated EGFR-mutant NSCLC patients (2+ prior lines)
+7 more records
Product overview1 text field

Voronoi is a precision medicine company developing novel targeted kinase inhibitors for oncology and autoimmune diseases. Its core proprietary platform, VORONOMICS, integrates wet-lab data (550,000+ compound assays per year) with AI to accelerate drug discovery, achieving candidate development timelines of 1–1.5 years. The company maintains a pipeline of eight programs spanning lung cancer (VRN11, a 4th-gen EGFR inhibitor), breast and solid tumors (VRN10, a HER2-selective inhibitor), partnered EGFR/HER2 exon 20 assets (VRN07 with ORIC Pharmaceuticals), gynecologic cancers (VRN16/PKMYT1 and VRN19/USP1), an autoimmune therapy (VRN04/RIPK1, transferred to Anvia), and pulmonary hypertension (VRN13, inhaled PDGFR inhibitor). The portfolio emphasizes two key differentiators: exquisite kinase selectivity and high blood-brain barrier penetration.

Product and service8 records
1VORONOMICS Platform
CategoryDrug discovery platform
Description

Proprietary drug discovery platform that combines wet-lab data (~550,000 compound assays annually) with AI/ML modeling to rapidly identify and optimize drug candidates engineered for exquisite kinase selectivity and superior blood-brain barrier penetration. Used by Voronoi to generate its internal pipeline of kinase inhibitors.

2VRN11 (REACH-EGFR)
CategoryOncology kinase inhibitor (EGFR)
Description

Fourth-generation, orally bioavailable EGFR-selective tyrosine kinase inhibitor targeting common (Del19, L858R), uncommon (G719X, L861Q, S768I), and resistance (C797S) EGFR mutations in non-small cell lung cancer. Demonstrates superior blood-brain barrier penetration (Kp,uu,CSF of 2.0 vs ~0.2 for osimertinib) and favorable safety (no DLTs up to 480mg). Phase 1a DCR of 96.8% (30/31) in heavily pretreated EGFR-mutant NSCLC patients.

3VRN10 (LUMIN-HER2)
CategoryOncology kinase inhibitor (HER2)
Description

Orally bioavailable, highly selective covalent HER2 tyrosine kinase inhibitor for HER2-positive solid tumors including breast cancer. Active across HER2 mutation subtypes and HER2 amplification, with synergy with HER2 ADCs (trastuzumab deruxtecan/Enhertu) and activity in T-DXd-resistant tumors. Phase 1a HER2 mutation cohort ORR 43% (3/7), DCR 86% (6/7).

4VRN07 (ORIC-114)
CategoryOncology kinase inhibitor (EGFR/HER2 exon20)
Description

EGFR/HER2 exon 20 insertion inhibitor for EGFR and HER2 exon 20 mutation-driven solid tumors, partnered with ORIC Pharmaceuticals (Nasdaq-listed) under an October 2020 license agreement with USD 621M total deal value. Demonstrates high brain penetration.

5VRN16
CategorySynthetic lethality oncology (PKMYT1)
Description

Novel selective orally available PKMYT1 inhibitor leveraging synthetic lethality mechanism, targeting CCNE1-amplified cancers including ovarian, uterine, gastric, and breast cancers. CCNE1 amplification occurs in approximately 8% of solid tumors. Preclinical data demonstrate differentiated selectivity, tolerability, and anti-tumor activity.

6VRN19
CategorySynthetic lethality oncology (USP1)
Description

Best-in-class orally available USP1 inhibitor targeting BRCA1/2-mutated cancers (ovarian, breast) via synthetic lethality. Demonstrates superior tolerability and potent anti-tumor activity with a broad therapeutic window compared to competing USP1 inhibitors.

7VRN04
CategoryAnti-inflammatory / autoimmune kinase inhibitor (RIPK1)
Description

Orally available RIPK1 inhibitor targeting TNF-alpha receptor signaling for chronic inflammatory and autoimmune diseases. Transferred to Anvia Therapeutics via asset purchase agreement (competing with programs from Eli Lilly and Sanofi). Voronoi received equity and milestone-based consideration.

8VRN13
CategoryInhaled pulmonary therapy (PDGFR)
Description

Best-in-class inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH). Localized pulmonary delivery reduces systemic exposure and avoids neurological adverse events associated with oral PDGFR inhibitors such as imatinib.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeOthersAnnounced on2026-02-03
Description

Voronoi conducted an independent 18-month review of Australia's Sparked FHIR Standards Accelerator Program as a digital health consultancy, finding it 'highly effective' and recommending the development of a national FHIR Standards Roadmap. This represents a non-core consulting engagement for Voronoi as a digital health consultancy.

2Anvia Therapeutics
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-26
Description

Voronoi entered into an option agreement with Anvia Therapeutics (US biotech founded by Deerfield) for VRN04, a RIPK1 inhibitor for chronic inflammation and autoimmune diseases. Voronoi received 2.5M shares of Anvia common stock as option fee, with additional equity and cash to be received upon option exercise. Final purchase agreement was signed September 2025, with Voronoi receiving an additional 3M Anvia shares as upfront payment. VRN04 targets TNF-alpha receptor signaling for anti-inflammatory effects, competing with programs from Eli Lilly and Sanofi.

voronoi.io
3Korean Ministry of Food and Drug Safety (MFDS)
Strategic tierMinorTypeOthersAnnounced on2023-07-04
Description

Voronoi's clinical programs (VRN11, VRN10) have received IND approvals from the Korean Ministry of Food and Drug Safety (MFDS/Korean FDA), enabling clinical trials in Korean patients. The MFDS regulatory pathway complements approvals from Australian TGA, Taiwan FDA, and US FDA.

voronoi.io
4Pyramid Biosciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-11-17
Description

Voronoi out-licensed MPS1 target solid tumor treatment candidate (VRN08) to Pyramid Biosciences (Boston-based, US) for total deal value of up to $846M (~KRW 1 trillion). Pyramid, founded by executives from Pfizer, Boehringer Ingelheim, Roche, BMS, planned to develop VRN08 for breast cancer and other solid tumors, leveraging a strong oncology advisory board from Harvard, Stanford, and MGH. The program was also supported by Korea's National New Drug Development Project (KDDF).

voronoi.io
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-08-01
Description

Voronoi out-licensed DYRK1A target autoimmune and neuroinflammatory disease program to Bridgepoint (Nasdaq-listed, US, founded by executives from Eli Lilly, Novartis, Allergan) for upfront of $5M and total deal value of up to $323.5M (~KRW 380 billion). Bridgepoint planned to develop the candidate for psoriasis, ulcerative colitis, Crohn's disease, and neuroinflammation, with Phase 1 planned for 2022.

6Korea National Enterprise for Chimera (KDDF/National New Drug Development Project)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Multiple Voronoi pipeline programs (VRN04, VRN08, VRN10, VRN11, VRN13) have been selected for the Korean government's National New Drug Development Project (KDDF). The KDDF provides preclinical research funding and development support, validating the scientific merit of Voronoi's programs. Preclinical support amounts for VRN11 included ~KRW 1.2 billion over 2 years.

voronoi.io
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-10-20
Description

Voronoi out-licensed EGFR/HER2 exon20 insertion mutation NSCLC and solid tumor treatment candidate to ORIC Pharmaceuticals (Nasdaq-listed, US) for upfront payment of $13M and total deal value of up to $621M (~KRW 720 billion). ORIC acquired global rights (excluding Greater China) and initiated Phase 1/2 clinical trials in H2 2021. Voronoi retains ~10% royalty on net sales upon commercialization. This deal served as the first major validation of Voronoi's technology platform and its first unicorn-tier technology export.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted therapies against difficult oncology targets including RAS(ON) inhibitors. Direct comparability with Voronoi on kinase/inhibitor design philosophy, targeted oncology focus, and US-listed biotech business model.

2Nuvalent
TypeDirect peer
Description

Clinical-stage biotech developing precisely designed kinase inhibitors for cancer, with explicit emphasis on selectivity, brain penetration, and overcoming resistance mutations. Closest direct analog to Voronoi's VRN11/VRN10 design philosophy.

TypeDirect peer
Description

Nasdaq-listed precision oncology company that licensed EGFR/HER2 exon20 assets (VRN07) from Voronoi. Both companies focus on resistance-overcoming oncology kinase inhibitors, with ORIC serving as both a licensee partner and a structurally similar US-listed biotech.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule kinase inhibitors targeting cancer drivers and resistance mutations. Comparable business model (targeted kinase inhibitors for oncology) and stage (Phase 1/2 assets).

TypeDirect peer
Description

Clinical-stage oncology company developing a diversified pipeline of targeted therapies including kinase inhibitors. Comparable in stage, business model, and precision oncology focus to Voronoi.

TypeDirect peer
Description

AI-driven drug discovery company using high-throughput biology and machine learning to identify novel therapeutics. Comparable to Voronoi's VORONOMICS platform in combining wet-lab data with AI for accelerated drug design.

TypeDirect peer
Description

AI-driven pharmatech company that designs and develops precision medicines using its AI platform. Comparable to Voronoi's VORONOMICS in AI-augmented drug design, with similar focus on speed and selectivity.

TypeDirect peer
Description

Clinical-stage biotech developing targeted therapies for genetic diseases and cancers, with a multi-asset pipeline and licensing/partnership business model. Comparable to Voronoi in pipeline breadth and partnership-driven commercialization approach.

TypeRegional player
Description

Korean pharmaceutical company developing innovative oncology and specialty therapeutics. Comparable regional Korean biotech/pharma peer to Voronoi, though operating at larger scale and with more mature commercial products.

TypeDirect peer
Description

Precision oncology company (acquired by Bristol Myers Squibb in 2024) that developed targeted kinase inhibitors including KRAS G12C inhibitor Krazati. Direct comparability with Voronoi on precision oncology kinase inhibitor focus and US-listed biotech profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Voronoi

Precision Oncology Therapeuticsvoronoi.io

Voronoi is a Korean clinical-stage biotech using its AI-augmented VORONOMICS platform to develop precision kinase inhibitors for oncology and autoimmune diseases, commercializing through global out-licensing deals.

What Voronoi does

Voronoi is a precision medicine biotechnology company founded in 2015 and headquartered in Songdo, Incheon, South Korea, that develops novel kinase inhibitors and target protein degraders for oncology and autoimmune diseases. The company's core technology is VORONOMICS, a proprietary AI-augmented drug design platform that integrates in-house wet-lab kinase profiling data (~550,000 assay data points per year) with machine learning feedback loops and an in vivo animal testing center to identify and optimize candidates with high selectivity and blood-brain barrier penetration, compressing candidate identification timelines to 1–1.5 years versus an industry-standard ~3 years. Voronoi maintains an 11-program pipeline spanning EGFR-mutant NSCLC (VRN11), HER2-positive solid tumors (VRN10), EGFR/HER2 exon 20 insertions (VRN07, partnered with ORIC), synthetic-lethality targets (VRN16/PKMYT1, VRN19/USP1), an autoimmune therapy (VRN04/RIPK1, transferred to Anvia), and an inhaled PAH therapy (VRN13). As of its 2022 securities filing, the company held 174 patents (186 total IP assets), ranking first in Korea and ninth globally in small molecule drug patents.

Voronoi firmographics

Firmographics
Name
Voronoi
Legal name
Voronoi, Inc.
Website
https://voronoi.io
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Voronoi is a Korean clinical-stage biotech using its AI-augmented VORONOMICS platform to develop precision kinase inhibitors for oncology and autoimmune diseases, commercializing through global out-licensing deals.
Ownership category
akta.pro rank

Voronoi industry classification

Industry
Product category
Precision Oncology Therapeutics
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Kinase inhibitor discovery
  • Precision oncology therapeutics
  • Targeted cancer therapy
  • Pharmaceutical out-licensing
  • AI drug discovery platform

Where Voronoi is headquartered

Location

Headquarters

HQ city
Incheon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Voronoi business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Technology Licensing / License-Out Deals: Voronoi's primary revenue model is out-licensing its proprietary drug candidates to global pharmaceutical and biotech companies. The company discovers and develops pipeline candidates through Phase 1 clinical stage, then executes license-out agreements that generate upfront payments, milestone payments, and ongoing royalties. Reference deals include: ORIC Pharmaceuticals (EGFR/HER2 exon20, ~$621M total), Bridgepoint (DYRK1A autoimmune, ~$323.5M total), Pyramid Biosciences (MPS1, ~$846M total), and Anvia Therapeutics (VRN04 RIPK1, equity + milestone payments). Cumulative technology export value exceeds KRW 3 trillion.
  2. Government Research Grants: Voronoi receives non-dilutive funding from Korea's National New Drug Development Project (KDDF) for preclinical and candidate discovery stages. Multiple pipeline programs (VRN04, VRN08, VRN10, VRN11, VRN13) have been selected for government support.
  3. Equity Capital / Public Market: Voronoi is listed on KOSDAQ (ticker: 310210). The company raises dilutive capital through public offerings, rights offerings, and convertible bond issuances to fund clinical development. IPO was completed in June 2022. Subsequent capital raises include a KRW 450 billion rights offering in 2023.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Voronoi product offering

Product offering

Core offering

Voronoi discovers and develops targeted kinase inhibitors and related small molecule therapeutics for oncology (EGFR-mutant NSCLC, HER2-positive solid tumors, CCNE1-amplified cancers, BRCA1/2-mutant cancers) and autoimmune/Pulmonary arterial hypertension indications using its proprietary VORONOMICS AI-augmented drug design platform. Its portfolio includes VRN11 (4th-generation EGFR inhibitor), VRN10 (HER2-selective inhibitor), VRN07 (EGFR/HER2 exon20 inhibitor partnered with ORIC), VRN16 (PKMYT1 inhibitor), VRN19 (USP1 inhibitor), VRN13 (inhaled PDGFR inhibitor for PAH), and VRN04 (RIPK1 inhibitor transferred to Anvia Therapeutics). Revenue is generated primarily through out-licensing these pipeline assets to global pharmaceutical partners in exchange for upfront, milestone, and royalty payments.

Product overview

Voronoi is a precision medicine company developing novel targeted kinase inhibitors for oncology and autoimmune diseases. Its core proprietary platform, VORONOMICS, integrates wet-lab data (550,000+ compound assays per year) with AI to accelerate drug discovery, achieving candidate development timelines of 1–1.5 years. The company maintains a pipeline of eight programs spanning lung cancer (VRN11, a 4th-gen EGFR inhibitor), breast and solid tumors (VRN10, a HER2-selective inhibitor), partnered EGFR/HER2 exon 20 assets (VRN07 with ORIC Pharmaceuticals), gynecologic cancers (VRN16/PKMYT1 and VRN19/USP1), an autoimmune therapy (VRN04/RIPK1, transferred to Anvia), and pulmonary hypertension (VRN13, inhaled PDGFR inhibitor). The portfolio emphasizes two key differentiators: exquisite kinase selectivity and high blood-brain barrier penetration.

Differentiator

Problem solved

Functional benefit

Products and services

  • VORONOMICS Platform Proprietary drug discovery platform that combines wet-lab data (~550,000 compound assays annually) with AI/ML modeling to rapidly identify and optimize drug candidates engineered for exquisite kinase selectivity and superior blood-brain barrier penetration. Used by Voronoi to generate its internal pipeline of kinase inhibitors.
  • VRN11 (REACH-EGFR) Fourth-generation, orally bioavailable EGFR-selective tyrosine kinase inhibitor targeting common (Del19, L858R), uncommon (G719X, L861Q, S768I), and resistance (C797S) EGFR mutations in non-small cell lung cancer. Demonstrates superior blood-brain barrier penetration (Kp,uu,CSF of 2.0 vs ~0.2 for osimertinib) and favorable safety (no DLTs up to 480mg). Phase 1a DCR of 96.8% (30/31) in heavily pretreated EGFR-mutant NSCLC patients.
  • VRN10 (LUMIN-HER2) Orally bioavailable, highly selective covalent HER2 tyrosine kinase inhibitor for HER2-positive solid tumors including breast cancer. Active across HER2 mutation subtypes and HER2 amplification, with synergy with HER2 ADCs (trastuzumab deruxtecan/Enhertu) and activity in T-DXd-resistant tumors. Phase 1a HER2 mutation cohort ORR 43% (3/7), DCR 86% (6/7).
  • VRN07 (ORIC-114) EGFR/HER2 exon 20 insertion inhibitor for EGFR and HER2 exon 20 mutation-driven solid tumors, partnered with ORIC Pharmaceuticals (Nasdaq-listed) under an October 2020 license agreement with USD 621M total deal value. Demonstrates high brain penetration.
  • VRN16 Novel selective orally available PKMYT1 inhibitor leveraging synthetic lethality mechanism, targeting CCNE1-amplified cancers including ovarian, uterine, gastric, and breast cancers. CCNE1 amplification occurs in approximately 8% of solid tumors. Preclinical data demonstrate differentiated selectivity, tolerability, and anti-tumor activity.
  • VRN19 Best-in-class orally available USP1 inhibitor targeting BRCA1/2-mutated cancers (ovarian, breast) via synthetic lethality. Demonstrates superior tolerability and potent anti-tumor activity with a broad therapeutic window compared to competing USP1 inhibitors.
  • VRN04 Orally available RIPK1 inhibitor targeting TNF-alpha receptor signaling for chronic inflammatory and autoimmune diseases. Transferred to Anvia Therapeutics via asset purchase agreement (competing with programs from Eli Lilly and Sanofi). Voronoi received equity and milestone-based consideration.
  • VRN13 Best-in-class inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH). Localized pulmonary delivery reduces systemic exposure and avoids neurological adverse events associated with oral PDGFR inhibitors such as imatinib.

Quantifiable outcome

  • VRN11 Phase 1a: DCR 96.8% (30/31) in heavily pretreated EGFR-mutant NSCLC patients (2+ prior lines)
  • +7 more outcomes

Companies that use Voronoi

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Voronoi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Voronoi partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Australian Government (via Sparked FHIR Standards Accelerator Program)minorOthers · 3 February 2026Voronoi conducted an independent 18-month review of Australia's Sparked FHIR Standards Accelerator Program as a digital health consultancy, finding it 'highly effective' and recommending the development of a national FHIR Standards Roadmap. This represents a non-core consulting engagement for Voronoi as a digital health consultancy.
  • Anvia TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 26 August 2024Voronoi entered into an option agreement with Anvia Therapeutics (US biotech founded by Deerfield) for VRN04, a RIPK1 inhibitor for chronic inflammation and autoimmune diseases. Voronoi received 2.5M shares of Anvia common stock as option fee, with additional equity and cash to be received upon option exercise. Final purchase agreement was signed September 2025, with Voronoi receiving an additional 3M Anvia shares as upfront payment. VRN04 targets TNF-alpha receptor signaling for anti-inflammatory effects, competing with programs from Eli Lilly and Sanofi.
  • Korean Ministry of Food and Drug Safety (MFDS)minorOthers · 4 July 2023Voronoi's clinical programs (VRN11, VRN10) have received IND approvals from the Korean Ministry of Food and Drug Safety (MFDS/Korean FDA), enabling clinical trials in Korean patients. The MFDS regulatory pathway complements approvals from Australian TGA, Taiwan FDA, and US FDA.
  • Pyramid BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 17 November 2021Voronoi out-licensed MPS1 target solid tumor treatment candidate (VRN08) to Pyramid Biosciences (Boston-based, US) for total deal value of up to $846M (~KRW 1 trillion). Pyramid, founded by executives from Pfizer, Boehringer Ingelheim, Roche, BMS, planned to develop VRN08 for breast cancer and other solid tumors, leveraging a strong oncology advisory board from Harvard, Stanford, and MGH. The program was also supported by Korea's National New Drug Development Project (KDDF).
  • Bridgepoint (Brigek Pharmaceuticals)coreOEM/ Whitelabel/ Licensing Partner · 1 August 2021Voronoi out-licensed DYRK1A target autoimmune and neuroinflammatory disease program to Bridgepoint (Nasdaq-listed, US, founded by executives from Eli Lilly, Novartis, Allergan) for upfront of $5M and total deal value of up to $323.5M (~KRW 380 billion). Bridgepoint planned to develop the candidate for psoriasis, ulcerative colitis, Crohn's disease, and neuroinflammation, with Phase 1 planned for 2022.
  • Korea National Enterprise for Chimera (KDDF/National New Drug Development Project)coreStrategic or Co-development Partner · 1 January 2021Multiple Voronoi pipeline programs (VRN04, VRN08, VRN10, VRN11, VRN13) have been selected for the Korean government's National New Drug Development Project (KDDF). The KDDF provides preclinical research funding and development support, validating the scientific merit of Voronoi's programs. Preclinical support amounts for VRN11 included ~KRW 1.2 billion over 2 years.
  • ORIC Pharmaceuticals (NASDAQ: ORIC)coreOEM/ Whitelabel/ Licensing Partner · 20 October 2020Voronoi out-licensed EGFR/HER2 exon20 insertion mutation NSCLC and solid tumor treatment candidate to ORIC Pharmaceuticals (Nasdaq-listed, US) for upfront payment of $13M and total deal value of up to $621M (~KRW 720 billion). ORIC acquired global rights (excluding Greater China) and initiated Phase 1/2 clinical trials in H2 2021. Voronoi retains ~10% royalty on net sales upon commercialization. This deal served as the first major validation of Voronoi's technology platform and its first unicorn-tier technology export.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Voronoi competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Clinical-stage precision oncology company developing targeted therapies against difficult oncology targets including RAS(ON) inhibitors. Direct comparability with Voronoi on kinase/inhibitor design philosophy, targeted oncology focus, and US-listed biotech business model.
  • Nuvalent: Clinical-stage biotech developing precisely designed kinase inhibitors for cancer, with explicit emphasis on selectivity, brain penetration, and overcoming resistance mutations. Closest direct analog to Voronoi's VRN11/VRN10 design philosophy.
  • ORIC Pharmaceuticals: Nasdaq-listed precision oncology company that licensed EGFR/HER2 exon20 assets (VRN07) from Voronoi. Both companies focus on resistance-overcoming oncology kinase inhibitors, with ORIC serving as both a licensee partner and a structurally similar US-listed biotech.
  • Kura Oncology: Clinical-stage precision oncology company developing small molecule kinase inhibitors targeting cancer drivers and resistance mutations. Comparable business model (targeted kinase inhibitors for oncology) and stage (Phase 1/2 assets).
  • Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of targeted therapies including kinase inhibitors. Comparable in stage, business model, and precision oncology focus to Voronoi.
  • Recursion Pharmaceuticals: AI-driven drug discovery company using high-throughput biology and machine learning to identify novel therapeutics. Comparable to Voronoi's VORONOMICS platform in combining wet-lab data with AI for accelerated drug design.
  • Exscientia: AI-driven pharmatech company that designs and develops precision medicines using its AI platform. Comparable to Voronoi's VORONOMICS in AI-augmented drug design, with similar focus on speed and selectivity.
  • BridgeBio Pharma: Clinical-stage biotech developing targeted therapies for genetic diseases and cancers, with a multi-asset pipeline and licensing/partnership business model. Comparable to Voronoi in pipeline breadth and partnership-driven commercialization approach.
  • Mirati Therapeutics: Precision oncology company (acquired by Bristol Myers Squibb in 2024) that developed targeted kinase inhibitors including KRAS G12C inhibitor Krazati. Direct comparability with Voronoi on precision oncology kinase inhibitor focus and US-listed biotech profile.

Regional players

  • Hanmi Pharmaceutical: Korean pharmaceutical company developing innovative oncology and specialty therapeutics. Comparable regional Korean biotech/pharma peer to Voronoi, though operating at larger scale and with more mature commercial products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Voronoi social profiles

Digital presence

Voronoi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Voronoi leadership team

Management profile

Number of profiles

Profiles17 records

Voronoi funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Voronoi M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voronoi

What does Voronoi do?

Voronoi discovers and develops targeted kinase inhibitors and related small molecule therapeutics for oncology (EGFR-mutant NSCLC, HER2-positive solid tumors, CCNE1-amplified cancers, BRCA1/2-mutant cancers) and autoimmune/Pulmonary arterial hypertension indications using its proprietary VORONOMICS AI-augmented drug design platform. Its portfolio includes VRN11 (4th-generation EGFR inhibitor), VRN10 (HER2-selective inhibitor), VRN07 (EGFR/HER2 exon20 inhibitor partnered with ORIC), VRN16 (PKMYT1 inhibitor), VRN19 (USP1 inhibitor), VRN13 (inhaled PDGFR inhibitor for PAH), and VRN04 (RIPK1 inhibitor transferred to Anvia Therapeutics). Revenue is generated primarily through out-licensing these pipeline assets to global pharmaceutical partners in exchange for upfront, milestone, and royalty payments.

Is Voronoi a public or private company?

Voronoi is a public company. It is classified as public and is currently operating.

When was Voronoi founded?

Voronoi was founded in 2015. It employs 51 to 100 people.

Where is Voronoi based?

Voronoi is headquartered in Incheon, South Korea, in the Asia region.

How does Voronoi make money?

Three revenue lines are on record. Technology Licensing / License-Out Deals are the primary driver. The others are government Research Grants and equity Capital / Public Market.

Who are Voronoi's main competitors?

Direct peers on record are Revolution Medicines, Nuvalent, ORIC Pharmaceuticals, Kura Oncology, Cullinan Oncology, Recursion Pharmaceuticals, Exscientia, BridgeBio Pharma and Mirati Therapeutics. Hanmi Pharmaceutical is listed as a regional player.

Does Voronoi have an API?

No public API is recorded for Voronoi.

What industry is Voronoi in?

Voronoi's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NateSamil Pharm hits upper limit…Voronoi jumps 15%[K-bio Pulse] : 네이트 뉴스Samik Pharmaceutical, JW Shinyak, and Voronoi all rose on the KRX, with Samik hitting its daily limit at 8,330 won. Samik's jump was unexplained, while JW Shinyak's 16% rise reflected hair loss sales and co-development, and Voronoi's 15% rise followed lung cancer data. Voronoi faces funding needs for global trials.NaverSamil Pharm hits upper limit...Voronoi jumps 15%[K-bio Pulse]Shares of Samik Pharmaceutical, JW Shinyak, and Voronoi rose sharply on Nov. 10 as the KOSPI and KOSDAQ rebounded over 4%. Samik hit its daily limit at 8,330 won, JW Shinyak up 16.35% to 2,455 won, and Voronoi up 14.67% to 111,800 won, with no new disclosures for Samik. Voronoi's lung cancer drug VRN11 showed 95% intracranial control in Phase 1 data.YahooVORONOI Receives KHIDI President’s Commendation for Global Open Innovation AchievementsVORONOI received a commendation from KHIDI for open innovation achievements, including five global technology transfer deals and technology asset sales. The company is advancing its EGFR-targeted therapy VRN11 in global Phase 1b/2 trials with IND approvals in Australia, Hong Kong, and Singapore. It plans to expand joint research and global partnerships.Business Wire BlogVORONOI Receives KHIDI President’s Commendation for Global Open Innovation AchievementsVORONOI received a commendation from KHIDI President at the 2026 Bio-Health Global Open Innovation Promotion Awards for open innovation achievements. The company has completed five technology transfer deals and asset sales, and its EGFR-targeted therapy VRN11 is in global Phase 1b/2 trials.SedailyKorean Biotech Startups Flock to Australia for Clinical TrialsKorean biotech startups are increasingly conducting clinical trials in Australia, with multiple companies disclosing Phase 1 trial approvals and results this year. Australia offers attractive incentives including refunds of up to 38.5% to 43.5% of R&D costs and a multi-ethnic population that facilitates bridging studies with high credibility for FDA and EMA approval. Notable companies including Inventage Lab, GI Innovation, Voronoi, and Biosolution have secured Australian IND approvals for treatments spanning Alzheimer's disease, immuno-oncology, and other conditions.Business StandardIndia plugged in too late, nears bottom in 2025 ePV rankings, shows dataIndia ranks 47th out of 51 countries in electric passenger vehicle adoption in 2025, with EVs comprising only 4% of new car sales (176,000 out of 4.5 million total), according to research by Voronoi using data from the International Energy Agency and Ember. The country is just above South Africa and Chile in global rankings, far behind its government target of 30% EV share by 2030, with the Ministry of Heavy Industries now estimating realistic adoption at only around 10%.PulseitSparked review calls for roadmapAn independent review of Australia's Sparked FHIR Standards Accelerator Program, conducted by digital health consultancy Voronoi over 18 months, found the program "highly effective" in building a vibrant community and producing detailed draft standards through collaboration. The review recommends developing a national FHIR Standards Roadmap to provide stakeholders with confidence and certainty for investing in interoperable solutions. Questions remain about sustainability of the current model, market adoption, and governance endorsement of standards against other program activities.BioWorldVoronoi presents new HER2 and/or HER4 inhibitorsVoronoi Inc. identified heteroaryl compounds that act as HER2 and/or HER4 inhibitors, reported to be useful for cancer treatment. The company's findings were presented at a conference on November 28, 2022.BioSpaceMETiS Announces Pan-RAF Inhibitor License Agreement with VoronoiMETiS Therapeutics entered a license agreement with Voronoi to develop and commercialize Voronoi's pan-RAF inhibitor worldwide. Voronoi will receive up to $1.7 million upfront and success-based milestones up to $480.5 million, plus tiered royalties. The program targets Class II and III BRAF mutant cancers, including CNS metastasis.